维立志博与Dianthus Therapeutics就其自免双抗LBL-047达成全球独家许可协议，潜在交易总额高达10亿美元

Core Viewpoint - The company has announced a global exclusive licensing agreement with Dianthus Therapeutics, Inc. to advance the clinical asset LBL-047, a novel anti-BDCA2-TACI bispecific fusion protein, which has received IND approval in the U.S. and acceptance in mainland China [1] Group 1: Licensing Agreement Details - Under the global exclusive licensing agreement, Dianthus will obtain exclusive rights to develop, manufacture, and commercialize LBL-047 outside of Greater China [1] - The company will receive an upfront payment of up to $38 million, along with potential milestone payments and up to $1 billion in potential clinical development, regulatory, and commercialization milestone payments [1] - The company will also be entitled to tiered royalties on net sales outside of Greater China, with rates ranging from single digits to low double digits [1] Group 2: Strategic Implications - The collaboration with Dianthus, recognized for its leadership and expertise in developing transformative therapies for severe autoimmune diseases, is expected to enhance the company's commitment to advancing innovative drug candidates into clinical stages [1] - The signing of the global exclusive licensing agreement aligns with the overall best interests of the company and its shareholders [1]